Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
VCP Double Nickase Plasmid (h): sc-401052-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- VCP Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- VCP Double Nickase Plasmid (h) and VCP Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting VCP. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: VCP Antibody (D-9): sc-133212
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VCP Double Nickase Plasmid (h) | sc-401052-NIC | 20 µg | $410.00 | |||
VCP Double Nickase Plasmid (h2) | sc-401052-NIC-2 | 20 µg | $410.00 |
Valosin-containing protein (VCP/p97) is an AAA+ ATPase that couples ATP hydrolysis to protein extraction and remodeling events across multiple proteostasis pathways. VCP coordinates ubiquitin-dependent processing of substrates in ER-associated degradation (ERAD), the ubiquitin–proteasome system, and selective autophagy, and also contributes to chromatin-associated processes and cell-cycle regulation. Through interactions with adaptor proteins, VCP helps maintain protein homeostasis and stress responses, linking its activity to pathways governing mitochondrial quality control and inflammatory signaling. Dysregulated VCP function and mutation-associated perturbations have been implicated in multisystem proteinopathy phenotypes and neurodegenerative disease mechanisms, making it a relevant target for studying proteotoxic stress and cellular quality-control networks.
VCP Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the VCP locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within VCP. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt VCP function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of VCP-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.